Navigation Links
Galenea Awarded RC1 Challenge Grant to Develop Predictive In Vivo Models of Cognition
Date:10/6/2009

CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- Galenea Corp., a fully-integrated CNS drug discovery company, announced today that it has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009 (Recovery Act). This two-year grant from the National Institute of Mental Health addresses the specific topic of "Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders" within the challenge area of Translational Science. The grant provides approximately $1 million to support the development of an innovative model for predicting the activity of potential treatments for impaired cognition in diseases such as schizophrenia. The program is part of Galenea's ongoing effort to pioneer new practices for objective measures in CNS drug discovery.

Schizophrenia is a devastating mental illness affecting about 1% of the global population. Currently available treatments can ameliorate some of the symptoms including the hallmark delusions and hallucinations but are not effective at treating the social isolation or the cognitive defects that afflict people with the disease. Traditional methods for assessing changes in cognition, such as impairments in attention and working memory, are very limited. This makes the development of new treatments for cognitive impairment very challenging. Galenea's unique in vivo approach to evaluating potential drug candidates for their pro-cognitive effects could lead to novel therapeutics for schizophrenia and other psychiatric diseases.

"The award serves as an endorsement of our approach to developing revolutionary analytical tools for measuring neuronal function and thereby increases the likelihood that viable drug treatments will reach the market", said David Gerber, Galenea's founder and VP of CNS Research. "This technology is part of our broader proprietary platform for monitoring neuronal network activity. We believe our platform will generate drug candidates with truly novel modes of action and ultimately provide patients with more effective therapeutics."

The National Institutes of Health received over 20,000 applications in response to this request. "Given the intense competitive nature of these stimulus grants, we are thrilled to have been selected for an award", said Mark Benjamin, CEO of Galenea. "This funding will allow us to aggressively pursue this approach and potentially transform neuropsychiatric drug discovery."

About Galenea Corp.

Galenea is a fully-integrated drug discovery company developing novel therapeutics for CNS diseases with a focus on psychiatric disorders. Galenea has licensed technologies developed in the laboratories of Professor Susumu Tonegawa of MIT and Professor Maria Karayiorgou of Columbia University Medical Center (formerly of The Rockefeller University) and based on the calcineurin pathway and its role in schizophrenia pathogenesis. Based on these discoveries, Galenea established a multi-year R&D collaboration with Otsuka Pharmaceutical Co., Ltd. to generate breakthrough treatments for schizophrenia and related disorders. In addition to the partnership with Otsuka, Galenea is building a proprietary technology platform based on profiling synaptic signatures of disease and advancing their selective 5-HT2C agonist towards the clinic. For more information about Galenea, please visit the company's website at www.galenea.com.

SOURCE Galenea Corp.


'/>"/>
SOURCE Galenea Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
2. USC neuroscientists awarded $9 million to map gene expression during human brain development
3. $16.8 million grant awarded to develop platelet recovery treatments
4. The Ambrosia Treatment Centers Awarded Gold Seal of Approval by the Joint Commission
5. Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine
6. Loyola University Chicago awarded scholarships for accelerated nursing students
7. Brookhaven Labs Joanna Fowler to be awarded National Medal of Science
8. Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant
9. Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent
10. $450,000 Awarded for Innovative Asthma Research Into Death by Drowning in Mucus
11. BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... (PRWEB) , ... August 24, 2017 , ... ... supplements that help people improve all aspects of their health and wellness, has ... , The step represents a component of Natural Subsistence’s aggressive marketing strategy in ...
(Date:8/24/2017)... ... August 24, 2017 , ... AudioEducator is the country’s top ... coming months, AudioEducator has lined up several training sessions on ICD-10 coding ... experts, these healthcare training conferences are designed to update providers with all the ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... President Business Development and Sector Growth. Mr. Smith joins other recent high-profile hires ... , Mr. Smith’s healthcare career began in 1993, helping physician practices and hospitals ...
(Date:8/23/2017)... ... ... The Stevie® Awards have announced the winners of the Best of the IBA Awards in ... , Nominees in the 2017 IBAs were not able to apply for the Best of ... number of awards won in the IBAs with a Gold Stevie win counting for three ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... MD , has returned home to Indiana, and is now seeing patients at ... board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye disease, medical ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology: